PhaseV

PhaseV develops AI and machine learning software for clinical development, serving biopharma sponsors and contract research organizations (CROs). Its causal machine learning technology is applied to clinical and real-world data to uncover hidden signals across large numbers of covariates, support trial design decisions, and enable real-time adaptation during a trial. Early service lines covered assessment of whether an adaptive design would benefit a proposed study followed by optimal design and execution, and retrospective analysis of trial data to evaluate endpoints and subpopulations, including re-examining whether a trial succeeded or failed.

The company describes its offering as a vertical AI platform spanning end-to-end clinical development, comprising four core applications: Trial Optimizer, for optimizing and implementing Bayesian, adaptive and fixed trials; Causal ML, for heterogeneous treatment effect estimation used to identify subpopulations and endpoints with the highest likelihood of success; Causal Disease Modeling, to inform R&D and life-cycle management decisions; and Clinical Operations, covering Causal ML-driven site selection, site performance analytics, real-time trial progress monitoring and integration of virtual control arms. The platform is supported by a data lake combining patient-level data, clinical trial results, real-world evidence and peer-reviewed literature, and is used across more than 20 therapeutic areas including neurology, oncology, gastrointestinal disorders, immunology, metabolic diseases and rare diseases.

Founding story

PhaseV was founded by Elad Berkman and Dr. Raviv Pryluk, who previously managed large multidisciplinary groups at technology companies with hands-on experience in machine learning, causal inference and software development at scale. Dr. Dan Goldstaub, who had managed clinical trials at Teva and MSD, joined as scientific co-founder. Pryluk serves as CEO.

Business model

PhaseV licenses and delivers its AI/ML clinical development platform and associated analytical work to biopharma sponsors and CROs, positioning the engagements around measurable return on investment through higher trial success rates, lower costs and faster time to market. Engagements include collaborative work with sponsors' internal clinical teams, as described by EMD Serono regarding subgroup identification using Causal ML.

Traction

The company reports having delivered results for more than 30 global pharma/biotech sponsors and CROs, with platform use spanning over 20 therapeutic areas. Reported outcomes include a 50% reduction in trial costs, 40% decrease in enrollment size and trial duration, and an increase of more than 30% in the likelihood of trial success; in one case it states it helped a global pharma company shorten time-to-market by 15 months.

Latest developments

In May 2025 PhaseV closed a $50 million Series A co-led by Accel and Insight Partners, with existing investors Viola Ventures, EXOR and LionBird participating, taking total funding to $65 million; proceeds are earmarked for expanding the vertical AI platform, including precision medicine capabilities, and broadening operations. The company has also published an independent industry survey on trial reporting and data workflow delays and sponsored the Timmerman Traverse benefiting the Damon Runyon Cancer Research Foundation.